Developing Precision Combination Therapies to Overcome Evolution of Therapeutic Resistance

Developing Precision Combination Therapies to Overcome Evolution of Therapeutic Resistance

Publication date: Mar 13, 2019

Presented At:

LabRoots – Drug Discovery Virtual Event 2019

Presented By:

Khyati Shah, PhD – Post Doctoral Research Scholar at University of California, San Francisco

Speaker Biography:

Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in breast cancer. Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.

Webinar:

Developing Precision Combination Therapies to Overcome Evolution of Therapeutic Resistance

Webinar Abstract:

Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic response. These patients with residual disease, progress upon therapy and develop acquired resistance and derive limited survival. Tumors are proficient at developing resistant to therapies, and the molecular mechanisms of therapeutic resistance are critical to pinpointing strategies to prevent these escape routes and to obtain long-lasting clinical responses. Using clinical specimen of disease progression, a majority of genetic alterations have been characterized and shown to co-exists upon acquired resistance, hence targeting single genetic driver would be futile to combat poly-clonal resistance. Therefore, there is an increasing need to find a targetable approach to prevent the evolution of resistance and yield a complete therapeutic response to abrogate the residual disease.

Learning Objectives:

1. Define the limitation of therapeutic resistance in drug discovery

2. Design the strategy to overcome resistance

3. Identify basis of resistance evolution

Earn PACE/CME Credits:

1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-event/drug-discovery-2019)

2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtual-event/drug-discovery-2019)

3. Click Here to get your PACE (Expiration date – February 27, 2021 10:30 AM)- https://www.labroots.com/credit/pace-credits/3241/third-party

LabRoots on Social:

Facebook: https://www.facebook.com/LabRootsInc

Twitter: https://twitter.com/LabRoots

LinkedIn: https://www.linkedin.com/company/labroots

Instagram: https://www.instagram.com/labrootsinc

Pinterest: https://www.pinterest.com/labroots/

SnapChat: labroots_inc

Concepts Keywords
Ado Food
Afar Immuno therapy systems
Akt Mum s energy
AM Patient tumor
Antibodies Recipe disease
Anxiety Therapy patient melanoma
Artemis Weeks regression tumor
Badgers Limited survival Tumors
BBC Pain
Bear Growth Tumor
Biological Drug Genomic driver tumor
Biomarker Patient s tumor
Blood Chemo
Bone Chemotherapy
Breakthrough Drug Immunotherapy
Breast Cancer Bypass
California Drug therapy
Cancer Medicine
Carrie Clinical medicine
Cash Cab Health
Chalk Antineoplastic drugs
Chemotherapy Oncology
Chinese Cancer treatments
Choir Chemotherapy
Clinical Trial Drug resistance
Clinical Trials Combination therapy
Clonal Targeted therapy
Clone Antineoplastic resistance
Combination Therapy Antibodies
Constipation Apoptosis
Continuing Education Drug discovery
Convict Chemotherapy
Dance Ado
Deejay Drug development
Devil
Divorce
Drug Development
Drug Discovery
Drug Resistance
Drug Target
Drug Therapy
Drug Tolerance
Drug Trial
Egg
Egypt
Epic
Eugenic
Evolution
Facebook
Faridi
Fart
FINA
Force
Ford
Genesis
Genetic
Genome
Google
Graft
Growth Factor
Histological
Horn
Hydroxyl
Hyperactivity
Ikea
Immunotherapy
Inhibitor
Instagram
Intrinsic Factor
Jaafari
Kindness
LinkedIn
Lung
Lung Cancer
Martyr
Material Good
Matrix
Mechanism Design
Melanoma
Microscopy
Modulation
Molecule
Morphology
Mutation
Oncology
Paradigm
Parapet
Parchment
Pharmaceutical Companies
Pharmaceutical Industry
Pharmacological
PhD
Pinterest
Post Mortem
Proteomic
Receptor
Refractory
Regression
Russian
San Francisco
Sells Green
SnapChat
Social Networking Website
Stockton
Synergistic
Tamoxifen
Targeted Therapy
Ter
Theology
Thes
Tic
Toph
Transit
Tree
Tumor
Turkey
War
Waterfall
Webinar
YouTube

Semantics

Type Source Name
drug DRUGBANK Coenzyme M
gene UNIPROT FURIN
disease MESH disease progression
disease DOID cancer
disease MESH cancer
pathway BSID Breast cancer
disease DOID breast cancer
disease MESH breast cancer
drug DRUGBANK Tamoxifen
gene UNIPROT AKT1
gene UNIPROT LAT2
gene UNIPROT NAA50
gene UNIPROT SLC35G1
gene UNIPROT PDC

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *